PDB Short entry for 2PCT HEADER SERINE PROTEINASE 13-JUN-94 2PCT TITLE MODELS OF THE SERINE PROTEASE DOMAIN OF THE HUMAN TITLE 2 ANTITHROMBOTIC PLASMA FACTOR ACTIVATED PROTEIN C AND ITS TITLE 3 ZYMOGEN COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN C; COMPND 3 CHAIN: A; COMPND 4 EC: 3.4.21.69; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1 KEYWDS SERINE PROTEINASE EXPDTA THEORETICAL MODEL AUTHOR C.L.FISHER,J.S.GREENGARD,J.H.GRIFFIN REVDAT 1 31-JUL-94 2PCT 0 JRNL AUTH C.L.FISHER,J.S.GREENGARD,J.H.GRIFFIN JRNL TITL MODELS OF THE SERINE PROTEASE DOMAIN OF THE HUMAN JRNL TITL 2 ANTITHROMBOTIC PLASMA FACTOR ACTIVATED PROTEIN C JRNL TITL 3 AND ITS ZYMOGEN. JRNL REF PROTEIN SCI. V. 3 588 1994 JRNL REFN ASTM PRCIEI US ISSN 0961-8368 REMARK 1 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2PCT COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998 REMARK 5 REMARK 5 THESE COORDINATES WERE GENERATED BY HOMOLOGY MODELING ONTO REMARK 5 THE X-RAY CRYSTAL STRUCTURES OF CHYMOTRYPSINOGEN, THROMBIN, REMARK 5 AND TRYPSINOGEN. REMARK 6 REMARK 6 SITE *CAT* IS THE SERINE PROTEASE CATALYTIC TRIAD. REMARK 7 REMARK 7 THE SHEETS PRESENTED AS *B1* AND *B2* ON SHEET RECORDS REMARK 7 BELOW ARE ACTUALLY SIX-STRANDED BETA-BARRELS. THIS IS REMARK 7 REPRESENTED BY SEVEN-STRANDED SHEETS IN WHICH THE FIRST REMARK 7 AND LAST STRANDS OF EACH SHEET ARE IDENTICAL. REMARK 8 REMARK 8 THIS IS AN UNCLEAVED (ZYMOGEN) FORM. REMARK 9 REMARK 9 CROSS REFERENCE TO SEQUENCE DATABASE REMARK 9 SWISS-PROT ENTRY NAME PDB ENTRY CHAIN NAME REMARK 9 PRTC_HUMAN REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: NULL REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 158 -109.82 62.32 REMARK 500 MET A 213 -53.64 74.60 REMARK 500 SER A 270 -116.22 -171.87 REMARK 500 ALA A 310 -50.66 79.19 REMARK 500 ASN A 313 -64.01 76.55 REMARK 500 ARG A 314 -103.64 69.85 REMARK 500 SER A 336 -107.50 64.25 REMARK 500 ILE A 348 -57.75 68.17 REMARK 500 ASP A 351 131.33 86.28 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 GLN A 162 GLU A 163 -142.78 REMARK 500 LEU A 219 LEU A 220 140.18 REMARK 500 TYR A 390 GLY A 391 148.42 DBREF 2PCT A 133 408 UNP P04070 PRTC_HUMAN 175 450 SEQRES 1 A 278 ACE CYS HIS PRO ALA VAL LYS PHE PRO CYS GLY ARG PRO SEQRES 2 A 278 TRP LYS ARG MET GLU LYS LYS ARG SER HIS LEU LYS ARG SEQRES 3 A 278 ASP THR GLU ASP GLN GLU ASP GLN VAL ASP PRO ARG LEU SEQRES 4 A 278 ILE ASP GLY LYS MET THR ARG ARG GLY ASP SER PRO TRP SEQRES 5 A 278 GLN VAL VAL LEU LEU ASP SER LYS LYS LYS LEU ALA CYS SEQRES 6 A 278 GLY ALA VAL LEU ILE HIS PRO SER TRP VAL LEU THR ALA SEQRES 7 A 278 ALA HIS CYS MET ASP GLU SER LYS LYS LEU LEU VAL ARG SEQRES 8 A 278 LEU GLY GLU TYR ASP LEU ARG ARG TRP GLU LYS TRP GLU SEQRES 9 A 278 LEU ASP LEU ASP ILE LYS GLU VAL PHE VAL HIS PRO ASN SEQRES 10 A 278 TYR SER LYS SER THR THR ASP ASN ASP ILE ALA LEU LEU SEQRES 11 A 278 HIS LEU ALA GLN PRO ALA THR LEU SER GLN THR ILE VAL SEQRES 12 A 278 PRO ILE CYS LEU PRO ASP SER GLY LEU ALA GLU ARG GLU SEQRES 13 A 278 LEU ASN GLN ALA GLY GLN GLU THR LEU VAL THR GLY TRP SEQRES 14 A 278 GLY TYR HIS SER SER ARG GLU LYS GLU ALA LYS ARG ASN SEQRES 15 A 278 ARG THR PHE VAL LEU ASN PHE ILE LYS ILE PRO VAL VAL SEQRES 16 A 278 PRO HIS ASN GLU CYS SER GLU VAL MET SER ASN MET VAL SEQRES 17 A 278 SER GLU ASN MET LEU CYS ALA GLY ILE LEU GLY ASP ARG SEQRES 18 A 278 GLN ASP ALA CYS GLU GLY ASP SER GLY GLY PRO MET VAL SEQRES 19 A 278 ALA SER PHE HIS GLY THR TRP PHE LEU VAL GLY LEU VAL SEQRES 20 A 278 SER TRP GLY GLU GLY CYS GLY LEU LEU HIS ASN TYR GLY SEQRES 21 A 278 VAL TYR THR LYS VAL SER ARG TYR LEU ASP TRP ILE HIS SEQRES 22 A 278 GLY HIS ILE ARG NH2 FTNOTE 1 GLN 162 - GLU 163 OMEGA = 217.22 PEPTIDE BOND DEVIATES FTNOTE 1 SIGNIFICANTLY FROM TRANS CONFORMATION FTNOTE 2 LEU 219 - LEU 220 OMEGA = 140.18 PEPTIDE BOND DEVIATES FTNOTE 2 SIGNIFICANTLY FROM TRANS CONFORMATION FTNOTE 3 TYR 390 - GLY 391 OMEGA = 148.42 PEPTIDE BOND DEVIATES FTNOTE 3 SIGNIFICANTLY FROM TRANS CONFORMATION HET ACE A 132 6 HET NH2 A 409 3 HET CA 500 1 HETNAM ACE ACETYL GROUP HETNAM NH2 AMINO GROUP HETNAM CA CALCIUM ION FORMUL 1 ACE C2 H4 O FORMUL 1 NH2 H3 N FORMUL 2 CA CA 2+ HELIX 1 H1A GLU A 160 ASP A 164 5IRREGULAR 5 HELIX 2 H1B SER A 281 ARG A 286 1IRREGULAR 6 HELIX 3 H1C SER A 304 GLU A 307 1IRREGULAR 4 HELIX 4 H1 HIS A 328 MET A 335 1IRREGULAR 8 HELIX 5 H2 LYS A 395 LEU A 400 1IRREGULAR 6 HELIX 6 H3 LEU A 400 ARG A 408 1IRREGULAR 9 SHEET 1 B1 7 TRP A 183 ASP A 189 0 SHEET 2 B1 7 LYS A 193 HIS A 202 -1 N ALA A 198 O VAL A 185 SHEET 3 B1 7 TRP A 205 THR A 208 -1 N LEU A 207 O VAL A 199 SHEET 4 B1 7 ILE A 258 LEU A 263 -1 O ALA A 259 N THR A 208 SHEET 5 B1 7 LEU A 236 HIS A 246 -1 O GLU A 242 N HIS A 262 SHEET 6 B1 7 LEU A 220 LEU A 223 -1 N VAL A 221 O LEU A 238 SHEET 7 B1 7 TRP A 183 ASP A 189 -1 O LEU A 188 N LEU A 220 SHEET 1 B2 7 GLN A 293 GLY A 299 0 SHEET 2 B2 7 ASN A 319 VAL A 326 -1 O ILE A 323 N THR A 295 SHEET 3 B2 7 ASN A 342 ALA A 346 -1 O CYS A 345 N VAL A 326 SHEET 4 B2 7 GLY A 391 VAL A 396 -1 N GLY A 391 O ALA A 346 SHEET 5 B2 7 THR A 371 TRP A 380 -1 O TRP A 380 N VAL A 392 SHEET 6 B2 7 GLY A 362 PHE A 368 -1 N ALA A 366 O PHE A 373 SHEET 7 B2 7 GLN A 293 GLY A 299 -1 O LEU A 296 N VAL A 365 SSBOND 1 CYS A 141 CYS A 277 SSBOND 2 CYS A 196 CYS A 212 SSBOND 3 CYS A 331 CYS A 345 SSBOND 4 CYS A 356 CYS A 384 SITE 1 CAT 3 HIS A 211 ASP A 257 SER A 360 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 HETATM 1 C ACE A 132 -16.621 21.319 4.502 1.00 0.00 C HETATM 2 O ACE A 132 -16.553 22.371 5.127 1.00 0.00 O HETATM 3 CH3 ACE A 132 -16.736 21.326 2.992 1.00 0.00 C HETATM 4 1H ACE A 132 -17.670 20.838 2.677 1.00 0.00 H HETATM 5 2H ACE A 132 -16.737 22.362 2.638 1.00 0.00 H HETATM 6 3H ACE A 132 -15.882 20.795 2.544 1.00 0.00 H